首页> 外文期刊>Expert opinion on biological therapy >New biological treatments for gynecological tumors: Focus on angiogenesis
【24h】

New biological treatments for gynecological tumors: Focus on angiogenesis

机译:妇科肿瘤的新生物疗法:专注于血管生成

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Gynecological tumors are a group of heterogeneous malignancies, with only modest results having been observed thus far with chemotherapy in advanced disease. New insights from pathobiology of these tumors have shed new light on potential new therapeutic targets. Angiogenesis is one of the most important processes involved in tumorigenesis, and effective treatments targeting the angiogenic machinery are now available. Areas covered: In this review, we will focus on angiogenesis as a therapeutic target in gynecological cancer patients. After a brief introduction on the angiogenesis machinery involvement in these malignancies, the most recent clinical data will be discussed. Expert opinion: Although clinical data with antiangiogenics are groundbreaking in several tumors such as ovarian epithelial cancer, overall efficacy of these agents is far from what was initially envisaged. As with other molecular targeted agents, selection of patients who may benefit from these agents will surely contribute to demonstrating better results. However, this does not diminish the clinical relevance of the above-mentioned results in a difficult field such as gynecological malignancies.
机译:简介:妇科肿瘤是一组异质性恶性肿瘤,迄今为止,在晚期疾病中进行化疗仅观察到适度的结果。这些肿瘤的病理生物学新见解为潜在的新治疗靶标提供了新的思路。血管生成是肿瘤发生中最重要的过程之一,现在有针对血管生成机制的有效治疗方法。涵盖的领域:在这篇综述中,我们将专注于血管生成作为妇科癌症患者的治疗靶标。在简要介绍血管生成机制参与这些恶性肿瘤后,将讨论最新的临床数据。专家意见:尽管抗血管生成剂的临床数据在诸如卵巢上皮癌的几种肿瘤中具有开创性意义,但这些药物的总体功效远非最初设想的那样。与其他分子靶向药物一样,选择可能受益于这些药物的患者肯定会有助于证明更好的结果。但是,在诸如妇科恶性肿瘤之类的困难领域中,这不会削弱上述结果的临床相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号